

Faculty:

Prof. Dr. med. Björn Chapuy
*Medical clinic for Hematology, Oncology
and Tumor Immunology | CBF
Charité - University Medicine
Berlin, Germany*

Dr. med. Johannes Düll
*Medical Clinic and Polyclinic II
University Hospital Würzburg
Würzburg, Germany*

Prof. Dr. med. Hermann Einsele
*Medical Clinic and Polyclinic II
University Hospital Würzburg
Würzburg, Germany*

Alexander Leipold
*Helmholz Institute for
RNA-based Infection Research
Würzburg, Germany*

Prof. Dr. med. Georg Lenz
*Clinic for Internal Medicine A: Hema-
tology, hemostaseology, Oncology and
Pneumology University Hospital Münster
Münster, Germany*

Prof. Dr. rer. nat. Roland Schmitz
*Molecular Cytology and
Functional Genomics
Department of Pathology
Justus Liebig University Giessen
Giessen, Germany*

Professor Laurie Sehn, MD PhD
*Faculty of Medicine
Medical Oncology
University of British Columbia
Vancouver, BC, Canada*

Professor Anna Sureda, MD PhD
*Hematology Department and Hemato-
poietic Stem Cell Transplant Programme
Institut Català d'Oncologia - Hospital
Duran i Reynals
Barcelona, Spain*

Prof. Dr. med. Max Topp
*Medical Clinic and Polyclinic II
University Hospital Würzburg
Würzburg, Germany*

Professor Umberto Vitolo, MD
*Candiolo Cancer Institute, FPO-IRCCS
Candiolo, Italy*

Prof. Dr. med. Rudolf Werner
*Department of Nuclear Medicine
Clinic for Radiology and Nuclear Medicine
University Hospital Frankfurt
Frankfurt am Main, Germany*

Scientific Chair/Host

Dr. med. Johannes Düll

Venue:

Hotel Melchior Park
Am Galgenberg 49
97074 Würzburg
Germany

With the kind support of our sponsor



Incyte Biosciences International Sàrl
Rue Dr Yersin 12
CH-1110 Morges

An event of:

Universitätsklinikum Würzburg A.ö.R.
Josef-Schneider-Straße 2
97080 Würzburg



www.ukw.de
www.medizin2.uk-wuerzburg.de
www.studienambulanz-wuerzburg.de

The contents of this event are designed to be product and service neutral. The organizer confirms, that the scientific chair and the speakers will disclose potential conflicts of interest to the participants. The event is sponsored by Incyte Biosciences International Sàrl with an amount of 78,242€. The total expenses of the event amount to approx 91.330.00€.

INVITATION & PROGRAM

DLBCL: New Horizons 2024

Friday 03/22/2024

Saturday 03/23/2024

Live in Würzburg and online!

Register now!



To get to the registration, click on
the button or scan the QR code.

<https://qrco.de/dlbcl-new-horizons-2024>

CME-certification is pending

Uniklinikum
Würzburg



Welcome letter

Dear colleagues!

The therapeutic landscape in DLBCL is constantly changing and new drugs are expanding our therapeutic options.

For a long time, R-CHOP was considered as first-line standard of care. With the Polarix trial there is a new therapeutic option available. CAR-T cells continue to establish themselves in the 2nd and 3rd line of therapy and bispecific antibodies are implemented in the relapse setting and pushing into the first line.

However, the many new options also pose a challenge to physicians to make the right treatment decisions.

We will therefore focus on which therapeutic options suit which patient. With our DLBCL preceptorship we are happy to offer a platform where we all can exchange ideas with colleagues and learn from each other.

Whether on site in Würzburg or live online: we are looking forward to a highly informative and exciting event and a lively exchange with you!

Best regards,



Johannes Düll
Senior physician
Universitätsklinik Würzburg

Program

Friday, March 22nd 2024

- | | |
|---------------|---|
| 15:00 - 15:15 | Welcome and introduction
Prof. Dr. med. Hermann Einsele
Dr. med. Johannes Düll |
| 15:15 - 16:00 | DLBCL What happend in the last 12 month? Any news?
Prof. Dr. med. Georg Lenz |
| 16:00 - 16:45 | Molecular Imaging in DLCBL
Prof. Dr. med. Rudolf Werner |
| 16:45 - 17:15 | Monitoring of ctDNA in DLBCL - Clinical Applications
Prof. Dr. rer. nat. Roland Schmitz |
| 17:15 - 17:45 | Coffee break |
| 17:45 - 18:15 | First line DLBCL - Lessons learned from Polarix
Professor Laurie Sehn, MD PhD |
| 18:15 - 19:30 | Second line DLBCL - CAR-T for all?
Professor Anna Sureda, MD PhD |
| 19:30 - 21:30 | Dinner |

Saturday, March 23rd 2024

- | | |
|---------------|---|
| 9:00 - 10:00 | Third line and beyond
- guidance through the new jungle
Prof. Dr. med. Max Topp |
| 10:00 - 10:45 | Real-World Experience with new drugs in DLBCL
Professor Umberto Vitolo |
| 10:45 - 11:00 | Coffee break |
| 11:00- 11:30 | New trials and drugs in DLBCL
Prof. Dr. med. Björn Chapuy |
| 11:30 - 12:15 | Sequencing immunotherapies and
its impact to molecular profiling of DLBCL
Alexander Leipold
Dr. med. Johannes Düll |
| 12:15 - 13:00 | Lunch break |
| 13:00- 13:15 | Conclusion and Farewell
Dr. med. Johannes Düll |